Skip to main content
logo
AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
201.55
-1.16 (-0.57%)
At close: May 8, 2026, 4:00 PM EDT
201.38
-0.17 (-0.08%)
After-hours: May 8, 2026, 7:57 PM EDT

AbbVie Revenue by Segment

Period EndingMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
Immunology
31.43B30.41B29.07B28.24B27.58B26.68B26.34B26.08B
Immunology Growth
13.99%13.96%10.38%8.27%6.39%2.09%-2.83%-6.78%
Neuroscience
11.36B10.77B10.32B9.84B9.32B9.00B8.58B8.26B
Neuroscience Growth
21.94%19.65%20.17%19.03%16.64%16.61%17.06%18.70%
Hematologic Oncology
6.65B6.66B6.68B6.69B6.65B6.56B6.37B6.20B
Hematologic Oncology Growth
0.12%1.53%4.85%7.89%9.98%10.82%5.57%0.37%
Aesthetics
4.94B4.86B4.87B4.92B5.03B5.18B5.25B5.25B
Aesthetics Growth
-1.69%-6.11%-7.18%-6.31%-4.08%-2.23%0.75%-0.44%
Other Products
3.92B3.74B3.76B3.63B3.56B3.65B3.70B3.79B
Other Products Growth
10.26%2.41%1.62%-4.24%-5.85%-4.15%-3.14%-1.51%
Eye Care
1.60B2.11B2.18B2.19B2.21B2.24B2.18B2.26B
Eye Care Growth
-27.47%-5.93%-0.28%-3.10%-5.76%-7.16%-9.88%-7.26%

Revenue by Geography

Period EndingMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
United States
47.59B46.60B45.54B44.62B43.97B43.03B42.41B42.11B
United States Growth
8.25%8.31%7.40%5.97%5.38%2.74%-1.30%-4.03%
International
15.23B14.56B14.10B13.71B13.40B13.31B13.13B12.89B
International Growth
13.63%9.41%7.41%6.31%5.68%7.00%7.85%6.12%

Operating Expense Breakdown

Period EndingMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018
Selling, General, and Administrative
14.30B14.01B13.97B14.61B14.73B14.75B14.09B13.26B--
Selling, General, and Administrative Growth
-2.95%-5.03%-0.85%10.18%12.03%14.61%7.59%1.76%--
Research and Development
9.50B9.10B13.29B13.10B12.92B12.79B7.94B7.54B--
Research and Development Growth
-26.46%-28.89%67.31%73.84%76.44%66.66%5.39%1.45%--
Acquired In-Process R&D
5.51B5.02B5.33B2.73B2.84B2.76B1.47B1.45B--
Acquired In-Process R&D Growth
94.02%81.94%263.48%88.20%258.71%254.37%98.24%103.23%--
Other Expenses
-434.00M-434.00M-48.00M-48.00M
Source: Business metrics provided by TipRanks and sourced from official company press releases and documents.